[en] This study compared the acute bronchial and hematologic effects of inhaled platelet activating factor (PAF) (30 micrograms as a single dose) in 19 patients with mild asthma and 19 normal subjects. Each subject underwent a methacholine bronchial challenge 1 week before PAF challenge to determine the concentration of methacholine causing a 20 percent fall in FEV1 (PC20M). On the day of PAF challenge, specific conductance (SGaw), FEV1, FEF25-75, and platelet and leukocyte counts were measured before, and 5, 10, 15, and 20 min after PAF inhalation. Changes in pulmonary and hematologic parameters were expressed as percent of control (saline solution/ethanol solution). Unlike normal subjects, subjects with asthma had bronchial hyperresponsiveness to methacholine: geometric mean (range): 0.59 mg/ml (0.07 to 9.8) vs > 32 mg/ml. Acute bronchial obstruction over the first 20 min after PAF inhalation was more pronounced in asthmatics than in normal subjects whatever the functional index considered (p < 0.01). In asthmatics (n = 19), mean (SEM) maximal fall in SGaw, FEV1, and FEF25-75 reached 50 percent (6), 11 percent (4), and 19 percent (5), respectively, while in normal subjects (n = 19) the maximal decreases were 24 percent (6), 4 percent (1), and 6 percent (1), respectively. In asthmatics, no correlation was found between log PC20M and log fall in FEV1 after PAF (r = 0.04 p > 0.05). In asthmatics and normal subjects, inhaled PAF caused a transient fall in neutrophils and monocytes by 5 min followed by a full recovery at 15 min and 20 min. These hematologic changes were not significantly different between the two groups. While not correlated with their airway responsiveness to methacholine, asthmatics, compared with normal subjects, develop an exaggerated acute airway obstruction in response to PAF. In contrast, hematologic changes induced by PAF do not differ between asthmatics and normal subjects.
Disciplines :
Cardiovascular & respiratory systems
Author, co-author :
Louis, Renaud ; Université de Liège - ULiège > Département des sciences cliniques > Pneumologie - Allergologie
Bury, Thierry ; Université de Liège - ULiège > Département des sciences de la motricité > Physiologie humaine et physiologie de l'effort physique
Corhay, Jean-Louis ; Université de Liège - ULiège > Pneumologie-Allergologie
Barnes PJ Chung KF Page RP Platelet activating factor as a modulator of allergic disease J Allergy Clin Immunol 81 1988 919 934
Rubin AE Smith JL Patterson R The bronchoconstrictor properties of platelet activating factor in humans Am Rev Respir Dis 136 1987 1145 1151
Chung KF Barnes PJ Effects of platelet activating factor on airway caliber, airway responsiveness and circulating cells in asthmatic subjects Thorax 44 1989 108 115
Louis R Bury TH Corhay JL Radermecker MF No increase in plasma histamine during PAF-induced airway obstruction in allergic asthmatics Chest 104 1993 806 810
Cuss FM Dixon CMB Barnes PJ Effects of inhaled platelet activating factor on pulmonary function and bronchial responsiveness in man Lancet 2 1986 189 192
Hopp R Bewtra A Agrawal D Townley R Effect of platelet activating factor inhalation on nonspecific bronchial reactivity in man Chest 96 1989 1070 1072
Lai C Jenkins J Polosa R Holgate S Inhaled PAF fails to induce airway hyperresponsiveness to methacholine in normal human subjects J Appl Physiol 68 1990 919 926
Kaye M Smith L Effects of inhaled LTD4 and platelet activating factor on airway reactivity in normal subjects Am Rev Respir Dis 141 1990 993 997
Wardlaw A Chung KF Moqbel R McDonald A Hartnell A McCusker M Effects of inhaled PAF in humans on circulating and bronchoalveolar lavage fluid neutrophils: relationship to bronchoconstriction and changes in airway responsiveness Am Rev Respir Dis 141 1990 386 392
Schellenberg RR Walker B Snyder F Platelet-dependent contraction of human bronchus by platelet activating factor [abstract] J Allergy Clin Immunol 71 1983 145A
Kroegel C Does airway smooth muscle care about platelet-activating factor Eur Respir J 5 1992 915 918
Spencer D An update on PAF Clin Exp Allergy 22 1992 521 524
Tokuyama K Lotvall JO Barnes PJ Chung KF Mechanism of airway narrowing caused by inhaled platelet activating factor: role of airway microvascular leakage Am Rev Respir Dis 143 1991 1345 1349
Cockcroft DW Killian DN Mellon JJ Hargreave FE Bronchial reactivity to inhaled histamine: a method and clinical survey Clin Allergy 7 1977 235 242
Hargreave FE Ryan G Thomson NC O’Byrne P Latiner K Juniper E Bronchial responsiveness to histamine and methacholine in asthma: measurement and clinical significance J Allergy Clin Immunol 68 1981 347 355
Hardy CC Robinson C Tattersfield E Holgate ST The bronchoconstrictor effect of inhaled prostaglandin D2 in normal and asthmatic men N Engl J Med 311 1984 209 213
Smith LJ Greenberger PA Patterson R Krell RD Bernstein PR The effects of inhaled leukotriene D4 in humans Am Rev Respir Dis 56 1985 323 327
Joos G Pauwels R Vanderstraeten M Effects of inhaled substance P and neurokinin A on the airways of normal and asthmatic subjects Thorax 42 1987 779 783
Chung KF Minette P McCusker M Barnes PJ Ketotifen inhibits the cutaneous but not the airway responses to platelet activating factor in man J Allergy Clin Immunol 81 1988 1192 1197
Tam FW Clague J Dixon CM Stuttle A Henderson B Peters A Inhaled platelet activating factor causes pulmonary neutrophil sequestration in normal humans Am Rev Respir Dis 146 1992 1003 1008
Zerbe GO Randomization analysis of the completely randomized design extended to growth and response curves J Am Stat Assoc 74 1979 215 221
Spencer DA Evans JM Green SE Piper PJ Costello JF Participation of the cysteinyl leukotrienes in the acute bronchoconstrictor response to inhaled platelet activating factor in man Thorax 46 1991 441 445
Kidney JC Ridge SM Chung KF Barnes PJ Inhibition of platelet activating factor induced bronchoconstriction by the leukotriene D4 receptor antagonist ICI 204, 219 Am Rev Respir Dis 147 1993 215 217
Johnson M The pharmacology of salmeterol Lung 68 suppl 1990 115 119
Spring J Johnston S Seale J Ind P Failure of salmeterol to inhibit circulating white cell responses and bronchoconstriction induced by platelet activating factor Thorax 47 1992 948 951
Chung KF Dent G Barnes PJ Effects of salbutamol on bronchoconstriction, bronchial hyperresponsiveness and leucocyte responses induced by platelet activating factor in man Thorax 44 1989 102 107
Jeffery PK Morphology of the airway wall in asthma and in chronic obstructive pulmonary disease Am Rev Respir Dis 143 1991 1152 1158
Pauwels R Joos G Vanderstraeten M Bronchial hyperresponsiveness is not bronchial hyperresponsiveness, is not bronchial asthma Clin Allergy 18 1988 317 321
Josephs L Gregg I Mullee M Holgate S Nonspecific bronchial reactivity and its relationship to the clinical expression of asthma Am Rev Respir Dis 140 1989 350 357
Peters M Breslin A Kemp A Chu J Berend N Haematological effects of inhalation of N-formyl-methionyl-leucyl-phenylalanine in man Thorax 47 1992 284 287
Braquet P Hosford D Braquet M Bourgain R Bussolino F Role of cytokines and platelet activating factor in microvascular immune injury Int Arch Allergy Appl Immunol 88 1989 88 100
Lammers J Kioumis I McCusker M Nichol G Barnes PJ Chung K Effects of prostacyclin on bronchoconstriction and neutropenia induced by inhaled platelet activating factor in man J Allergy Clin Immunol 85 1990 763 769
